GlassScriptPhysician profile
David D Houston
NPI 1386630309
$5,141.71
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $904 · 2021: $1,789 · 2022: $1,096.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $803.10 | 2019-2022 | |
| Abbvie INC. | $516.88 | 2021-2022 | |
| Lilly USA, LLC | $405.33 | 2019-2022 | |
| Pfizer INC. | $364.96 | 2019-2022 | |
| Amgen INC. | $344.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $340.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $265.20 | 2019-2022 | |
| Amarin Pharma, INC. | $151.00 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $150.83 | 2021 | |
| Astellas Pharma US INC | $149.66 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $110.74 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $96.72 | 2019-2022 | |
| Eisai INC. | $80.10 | 2021 |
Show all 40 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Houston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.